CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 42 enrolled
Drug / intervention
GSK249320 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00833989
NCT00833989Phase 2Completed
CompareCT.gov

A Single-Blind Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke

GlaxoSmithKline·interventional·Posted Feb 2, 2009·Updated Nov 17, 2017

In Brief

A Phase 2 clinical trial evaluating GSK249320 and PLACEBO for Ischaemic Attack, Transient. Completed, enrolled 42 participants across 15 sites in 3 countries.

Detailed Summary

The purpose of this study is to is to test increasing repeat doses of GSK249320 compared to placebo in patients with stroke.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschaemic Attack, Transient
CountriesCanada, Germany, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2, 2009
Enrollment StartJul 8, 2009
Primary CompletionJan 31, 2011
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 17.4 years ago

Interventions

GSK249320drug

I.V. infusion

PLACEBOdrug

Placebo